Company News: Page (1) of 1 - 04/15/18 Email this story to a friend. email article Print this page (Article printing at page facebook

Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors

- Broad Anti-Tumor Activity Observed across Multiple Tumor Types and RET Genotypes, with Radiographic Tumor Reductions in 84% of Evaluable Patients with RET-Altered Tumors -- Expansion Portion of ARRO... (April 15, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Presentors,Business,Business Issues,Internet Media,Presentation,Events, webcast, Inc.,AES Attendees,Medicine,Disease,medical technologists,Cancer,Technology,Surgery,Medication,Womens Health,Science,Medical Technology,Medical,Biology,Cancer,Business,Adults,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved